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Abstract
Introduction: Local synthesis of interferon within B16 tumors mediates anti-tumor effects. Based on reports that
stem cells are recruited to tumors, and because systemic administration of interferon causes dose-limiting
undesirable side effects, we wanted to improve the anti-tumor effects of interferon while simultaneously
minimizing its systemic side effects by employing mesenchymal stem cells (MSCs) as tumor-localized ectopic
producers of interferon. Many vectors exist to fulfill this purpose, but their transfection efficiency and resulting
expression levels vary considerably.
Methods: To follow both the recruitment to tumors and the synthesis of interferon by MSCs, we designed a
bicistronic vector system that permits fluorescent visualization of vector-transfected and interferon-producing MSCs.
We used Mu-IFNaA cDNA as the first cistron and the cherry fluorescent protein cDNA as the second cistron,
whose translation requires the internal ribosome entry sequence (IRES) from the encephalomyocarditis virus 5’
untranslated region. Observing inconsistent expression of these cistrons in various vectors and cell lines, especially
compared with a control plasmid pmaxGFP, we optimized the expression of this bicistronic message by mutating
pcDNA3 to facilitate exchange of the promoter and polyadenylation segments controlling both the gene of
interest and the eukaryotic antibiotic resistance gene as well as the eukaryotic antibiotic resistance gene itself, and
effectively compare the effects of these exchanges, creating plasmid pc3.5.
Results: Murine MSCs stably and ectopically expressing Mu-IFNaA inhibited the establishment of tumors in
homogeneic C57/BL6 mice. Mu-IFNaA expressed from the bicistronic message is fully biologically active, but is
expressed at only two-thirds of the level observed from a monocistronic message. Cap-dependent translation
is threefold more efficient than IRES-driven translation in 293T, B16, and MSC cell lines. Both efficient
expression and good transfection efficiency require strong expression of the gene of interest and a chimeric
intron. High doses of Mu-IFNaA within tumors inhibited tumor establishment but may not inhibit tumor
growth.
Conclusions: Our modified vector and its derived plasmids will find use in stem cell therapeutics, gene expression,
mRNA regulation, and transcription regulation. Local release of Mu-IFNaA within tumors may differently affect
tumor establishment and tumor growth.
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Many molecular biologists that perform experiments
involving ectopically expressed proteins work with a
number of plasmids. Some of these plasmids are well
validated, while others are used with little knowledge on
how they were synthesized or on their validated
sequence. Furthermore, each plasmid is generally
designed with a single purpose (for example, studying
promoters, ectopic expression, virus generation, or
exploring mRNA stability), and often exhibit significant
variation in their transfection efficiency within a given
cell line, and especially among various cell lines. To off-
set these variations, a diverse array of reagents have
been developed to transfect cell lines with particular
plasmids, or to transfect cell lines that strongly resist
taking in or expressing exogenous DNA such as
immune cell lines or primary cell lines.
Among these recalcitrant cell lines are embryonic or
adult stem cells. The latter have fewer ethic complica-
tions and, with improvements in their directed program-
ming, are enjoying widespread potential in basic,
translational, and clinical research in the treatment of
many physiological diseases, especially those in which
organ, tissue, or immune cell rebuilding or replacement
is a key requirement. Among the most widespread adult-
derived stem cells used for this research are mesenchy-
mal stem cells (MSCs). These cells are recruited to tis-
sues by chemotactic signals (often mediated by
chemokines) and perform key roles after being recruited
[1]. MSCs play a structural role during the rebuilding of
tissues, or differentiate into cells that perform infrastruc-
tural roles in the tissue or organ (for example, vascula-
ture, inter-organ compartmentalization) [1-3]. They also
help to locally suppress the immune system that may
detect these substantial tissue changes as a result of an
exogenous agent [4-7]. Finally, MSCs are easily extracted
from animals or from humans, minimizing immunologi-
cal complications arising from introducing engineered
cells or tissues and facilitating their use for tissue therapy.
Ironically, tumors recruit MSCs for largely similar
purposes. As tumor cells proliferate, they require tissue
support and integration with the circulatory system to
sustain the large mass of cells; they develop vasculature
and stroma derived from MSCs to fulfill these needs [8].
Additionally, the recruited MSCs may promote the local
immunosuppression of the immune system [4-7] that
functions innately to inhibit tumor growth. Nevertheless,
the recruitment of MSCs to tumors has been utilized by
several groups to try to deliver anti-tumor agents locally
to reduce both the overall dose as well as the concomi-
tant side effects to the patient.
Type I interferons such as IFNa are known to have
anti-tumor activity, based initially on their ability to slow
the proliferation of tumorigenic and transformed cell
lines. Our laboratory demonstrated that injection of B16
cells that ectopically express Mu-IFNaAf a i lt og r o wt o
become palpable tumors [9]. The same is true of B16
cells ectopically expressing Mu-IFNg and Mu-IFNl2
[10,11]; notably, these three interferons bind to distinct
receptors, act under distinct situations, and exhibit dis-
tinct physiological functions. Additionally, the effects of
interferon on tumor growth suppression are not
restricted to the tumor cells themselves. Interferons act
alone or can synergize with TNFa to inhibit proliferation
of endothelial cells and angiogenesis [12-15], and in this
way act to prevent tumor development. Type I interfer-
ons also influence the immune system: they enhance the
activity of natural killer cells that possess anti-tumor
activity [16-18], and they promote the upregulation of
class I MHC complexes and alter peptide presentation in
nonimmune cells to emphasize their detection by the
adaptive immune system [19,20]. Interferons thus impede
tumorigenesis by several distinct mechanisms.
The ectopic expression of type I interferons by MSCs
results in considerably slowed tumor growth when these
MSCs are injected into mice at the same time as injec-
tion of tumorigenic cells [21-26]. The reprogramming of
tissues or the treatment of tumors can thus be accom-
plished by genetically engineered MSCs. However, for
these MSCs to be useful, especially for a chronic disease
like cancer, one must prove that MSCs are effectively
targeted to the correct tissues, that the MSCs continue
to produce their ectopic gene of interest (GOI), and that
engineered MSCs persist in the host. Ideally, the expres-
sion of the GOI should also be restricted to the tissue
that is being reprogrammed. To accommodate these
quality-control requirements, one must select a proper
promoter and a reporter that is easily detected in tissue
sections or, if possible, in vivo. Also, implementation of
useful 3’ untranslated regions (UTRs) could further
refine the expression.
To address all of these needs that require distinct
genetic elements, we altered a well-validated plasmid
(we chose plasmid pcDNA3, originally marketed by Invi-
trogen, Carlsbad, CA, USA) to facilitate the introduction
of distinct genetic plasmid elements. We tested various
derivatives of this plasmid in cell lines that are used for
ectopic expression (human 293T cells), in murine mod-
els of aggressive melanoma (murine B16 melanoma
cells), and in murine MSCs. By implementing an inter-
nal ribosome entry sequence (IRES) from encephalo-
myocarditis virus (EMCV), we tightly coupled the
expression of the GOI and that of the reporter (in this
case, the cherry fluorescent protein (ChFP)) by con-
structing a bicistronic mRNA to ensure that transcrip-
tion of the GOI occurs. We found a surprising
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effective transfection efficiency. The predominant effec-
tors are the vector backbone and the strength of promo-
ter driving the GOI, while minor effects were seen by
altering the overall expression of the eukaryotic antibio-
tic resistance gene.
Materials and methods
Ethical approval
To perform the research within the present manuscript,
our laboratory received approval from the Institutional
Review Board of the Robert Wood Johnson Medical
School under protocol 021996W0149 (approved 22 Jan-
uary 1996) ‘Experimental Protocol for the Analysis of
Serum from Interferon Cytokines, Lymphokines and
Other Components’ and under protocol 021995W0188
(approved 22 February 2009) ‘Analysis of the Expression
of Cytokines and their Receptor Chains: IFNg,I F N a,
IFNb,I F N ν, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-18
and Related Class I and Class II Cytokines, and IL-10R1,
IL-10R2, IFNgR1, IFNgR2, IFNaR1, IFNaR2 Receptors
and Related Receptors JBP1, JBP2’.
To perform studies with live mice, we also received
approval from the Institutional Animal Care and Use
Committee at the Robert Wood Johnson Medical School
under protocol I07-128-12 (approved 16 December
2009) ‘Treatment of Malignancy in Mice Using Stem
Cells for Delivery of Biotherapeutics’.
Cell lines, media, and reagents
Human kidney epithelial 293T cells were obtained from
ATCC (Manassas, VA, USA) and were grown in DMEM
supplemented with 10% fetal bovine serum. Murine
C57BL/6 B16F0 aggressive melanoma cells were grown
in DMEM supplemented with 10% FCS. Monoclonal
murine C57BL/6 bone-marrow-derived MSCs were
obtained as previously described [8,10], and were grown
in DMEM supplemented with 10% fetal bovine serum
and 10 ng/ml human basic fibroblast growth factor,
obtained from Peprotech (Rocky Hill, NJ, USA). FCS
was obtained from Gemini BioProducts (Sacramento,
CA, USA). Representative clones harboring bicistronic
messages from stably transfected population were ampli-
fied by limiting dilution in 96-well dishes. Medium
inside wells containing stem cells was changed every 3
to 4 days because basic fibroblast growth factor is labile
at 37°C under our incubation conditions. Expanded
clones were visualized by fluorescence microscopy to
confirm the uniform expression of bicistronic messages
throughout the population. Only expanded monoclonal
populations are used in experiments with mice.
Pyrococcus furiosus (Pfu) DNA polymerase was
obtained from Stratagene/Agilent, Inc. (Santa Clara, CA,
USA). Thermus aquaticus (Taq) DNA polymerase, T4
DNA ligase, shrimp alkaline phosphatase, and all restric-
tion enzymes were obtained from NEB (Ipswich, MA
USA). All primers were obtained from Integrated DNA
technologies, Inc. (Coralville, IA, USA) and were used
without further purification other than desalting unless
specified.
Murine IFNaA (purified, 1,350 units/μl-a l s ok n o w n
as Mu-IFNa3; #12100-1) as well as rat anti-mouse
monoclonal neutralizing antibodies raised against Mu-
IFNaA (#22100-1) were gifts from PBL Interferon
Source (Piscataway, NJ, USA).
Polyethyleneimine (PEI) was obtained from Poly-
sciences, Inc. (Warrington, PA, USA) as a desiccated lin-
ear molecule averaging 25 kDa molecular weight.
Aqueous solutions of PEI (1 mg/ml) were prepared by
dissolution in water, and titration with hydrochloric acid
until the solution clears. After 1 hour, the solution is
neutralized to pH 7.1 with sodium hydroxide. After fil-
tration, aliquots were stored at -70°C until use. Metafec-
tene and Metafectene Easy were obtained from Biontex
GmbH (Planegg/Martinsreid, Germany). Fugene-6 and
Fugene HD were obtained from Roche Diagnostics
(Indianapolis, IN, USA). The Amaxa Nucleofection Kit
V was obtained from Amaxa/Lonza, Inc. (Gaithersburg,
MD, USA).
Site-directed mutagenesis of pcDNA3
We introduced several nucleotide mutations into the
pcDNA3 backbone to create unique restriction sites in
pcDNA3 that allow exchange of either the promoter-
driving sequences within the multicloning site, the 5’
UTR between the promoter and the multicloning site,
the 3’ UTR after the multicloning site, or the resistance
gene itself. Plasmids were mutated largely following the
protocol offered in the QuikChange site-directed muta-
genesis kit (Stratagene/Agilent, Inc.). Briefly, a 25 μl
reaction containing 2.5 μl of 10× Pfu polymerase buffer,
100 pmol forward primer and 100 pmol complementary
(reverse) primer (each purified by PAGE to remove mis-
synthesized primers that lower the efficiency of the pro-
tocol), 1 μl DMSO, 1 μlo f5 0m MM g C l 2,0 . 5μlo f5 0 ×
dNTP mix (10 mM each dNTP), 30 ng plasmid, 0.5 μl
(1.25 units) Pfu polymerase and water, was subjected to
PCR (in a Techgene thermal cycler; Techne, Cambridge,
UK) to amplify a mutated plasmid. After a 2-minute
incubation at 95°C, the solution was subjected to 18
cycles of: 30 seconds at 94°C; 1 minute at 55°C; and 18
minutes at 68°C, followed by 10 minutes at 72°C and
incubation at 4°C until used. Then 5 units of DpnI
restriction endonuclease was added to the reaction mix
to digest the parental plasmid, and the reaction was
incubated at 37°C for 90 minutes. Two 5 μla l i q u o t sa r e
removed and resolved by agarose gel electrophoresis
before and after the restriction digest to ensure the PCR
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digestion, a 2 μl aliquot was transformed into Escheri-
chia coli strain DH5a by chemical transformation. Plas-
mid DNA was isolated from well-isolated bacterial
colonies and an aliquot of that DNA was characterized
by restriction digest and/or sequencing reaction to con-
firm the mutagenesis. While describing the complemen-
tary primer pairs in this manuscript, only the sequence
of the forward primer is shown, although both it and its
reverse complement were used.
To create plasmid pc3.1, a ClaI site (which is not
digested in dam
+ E. coli strains) was inserted just before
the cytomegalovirus (CMV) promoter. The forward pri-
mer used to mutate pcDNA3 is: CTGCTTCGCGATG-
TACGGGATCGATATACGCGTTGACATTG. These
oligonucleotides overlap nucleotides 201 to 241 of plas-
mid pcDNA3. Mutated nucleotides compared with
pcDNA3 are set in boldface, and restriction sites (NruI,
ClaI, and MluI) are underlined.
To create plasmid pc3.2, AflII and HpaIs i t e sw e r e
inserted just 3’ of the transcription start site and prior
to the T7 primer sequence. The forward primer used to
mutate pc3.1 is: CTAGAGAACCCACTGCT-
TAAGGGGTTAACGAAATTAATACGACTCAC.
These oligonucleotides overlap nucleotides 829 to 875 of
plasmid pcDNA3. Mutated nucleotides compared with
pcDNA3 are set in boldface, and restriction sites (AflII
and HpaI) are underlined.
To create plasmid pc3.3, AgeI, SacII, and BsiWIs i t e s
were inserted just after the bovine growth hormone
polyadenylation signal and a PvuII site was concomi-
tantly removed. The forward primer used to mutate
pc3.2 is: CTGAGGCGGAAAGAACC-GCGGGCGTAC-
GAACCGGTATCCCCACGCGCCC. The dash in the
primers indicates that we intentionally deleted one
nucleotide from plasmid pc3.2 where a PvuII site laid.
These oligonucleotides overlap nucleotides 1,270 to
1,319 of plasmid pcDNA3. Mutated nucleotides com-
pared with pcDNA3 are set in boldface, and restriction
sites (AgeI, SacII, and BsiWI) are underlined.
To create plasmid pc3.4, a BssHII site was inserted
just prior to the simian virus-40 (SV40) promoter that
drives the neomycin resistance gene. The forward pri-
m e ru s e dt om u t a t ep c 3 . 3i s :C T G A T T T A A -
CAAAAATTTAGCGCGCATTAATTCTGTG-
GAATGTG. These oligonucleotides overlap nucleotides
1,713 to 1,756 of plasmid pcDNA3. Mutated nucleotides
compared with pcDNA3 are set in boldface, and the
BssHII restriction site is underlined.
We created plasmid pc3.5 from plasmid pc3.3 in a sin-
gle step by employing in a single reaction the primer
pair used to generate plasmid pc3.4 and a second pair
of primers that inserted a nonmethylated ClaIs i t e
before the SV40 polyadenylation motif and removed an
NaeI site. This second forward primer is:
GGAATCGTTTTCCGGGACATCGATTGGAT-
GATCCTCCAGCGC. These oligonucleotides overlap
nucleotides 3,044 to 3,085 of plasmid pcDNA3. Mutated
nucleotides compared with pcDNA3 are set in boldface,
and restriction sites (ClaI) are underlined.
Control experiments demonstrated that plasmid pc3.5
e x p r e s s e sp r o t e i n sa sw e l la sp c D N A 3i n2 9 3 Tc e l l sa n d
CHO cells, confers neomycin resistance to transfected
mammalian cell lines equivalent to that of pcDNA3, and
yielded as much plasmid from upon isolation from E. coli
as plasmid pcDNA3 (data not shown). A schematic of
the multifunctional plasmid pc3.5 is shown in Figure 1.
Polymerase chain reaction
Nearly all of the elements used in the present manu-
script were generated by PCR from either human geno-
mic DNA (isolated from 293T cells using Stratagene’s
large-scale genomic DNA isolation kit) or from various
plasmids. Either Taq or Pfu DNA polymerase were
used. Typically, reactions had a final volume of 50 to
100 μl and consisted of (in final concentrations) the
matched polymerase buffer, 500 μM each dNTP, 2 mM
MgCl2,1 0p m o lf o r w a r da n d1 0p m o lr e v e r s ep r i m e r s ,
either 5 ng plasmid or 1 μg genomic DNA, and 2.5
units polymerase. The amplification of the product was
done with the following conditions: 2 minutes at 95°C
and, 30 cycles of: 45 seconds at 94°C; 45 seconds at 5 to
10°C below the lowest Tm of the primer pair; and 1
minute/kbp (rounded up to the next higher minute) tar-
get length at 68°C (for Pfu polymerase) or 72°C (for Taq
polymerase), a final extension at 72°C for 10 minutes,
and incubation at 4°C until needed. PCR products were
cleaned of polymerase, buffer, primers and dNTPs with
the QIAQuick PCR purification kit (Qiagen, Inc., Valen-
cia, CA, USA). After their integration into a plasmid
vector, the entire PCR product was sequenced within
the plasmid using external primers to confirm sequence
integrity. The details of each PCR product and the pri-
mers used to amplify templates to create them are
described in Supplementary Text S1 in Additional file 1.
Vector construction
After digestion, all vector and insert fragments are
resolved by agarose gel (0.8 to 1.2% v:v) electrophoresis,
then purified by the QIAQuick gel extraction kit (Qia-
gen, Inc.). Ligations were done with up to 200 ng total
vector and insert in a total volume of 10 or 20 μl,
depending on whether a standard ligation with T4 DNA
Ligase or a Quick Ligase kit (both from New England
Biolabs, Inc.) were done. After ligation, an aliquot of the
mixture was transformed into chemically competent E.
coli DH5a cells prepared in-house by an established
protocol [27]. Well-isolated individual colonies were
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Figure 1 Schematic of plasmids pc3.5 and pmaxCDK. Unique restriction sites bordering various genetic elements of the plasmid are shown
for pc3.5 (top) or for pmaxCDK (bottom). Various defined genetic elements such as promoters, polyadenylation sequences, and antibiotic
resistance elements are labeled. Restriction sites bordering important eukaryotic genetic elements are shown. Sites within parentheses are not
unique within pc3.5 but become unique upon the following exchanges: neomycin ORF to either hygromycin or puromycin ORF (BssHII, PvuII
and NaeI), cytomegalovirus (CMV) promoter to the EF1A or cyclooxygenase (COX)-2 promoter (SpeI), and neomycin ORF to puromycin ORF (PstI).
Restriction sites set in red were introduced; the cryptic introduced ClaI site is set in blue. Middle: each plasmid used in this manuscript is shown,
with colored and labeled squares denoting a sequence that was introduced. Elements introduced include the human phosphoglycerate kinase
(PGK)-1 genomic promoter (in purple), a truncated human elongation factor-1a (EF1A) promoter (in red, see Figure 6), the human COX-2
genomic promoter (in yellow), the b-globin/IgG synthetic chimeric intron (in pink), the hygromycin resistance gene (in orange), the puromycin
ORF (in green), and the human PGK-1 polyadenylation sequence (in blue). BGH, bovine growth hormone; SV40, simian virus-40.
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sequence was verified by restriction digest and by
sequencing of PCR-derived inserts. The details of each
plasmid synthesized are described in Supplementary
Text S2 in Additional file 2; most of these plasmids are
depicted schematically in Figure 1.
Transfection and antibiotic selection
Cells were transfected with PEI using modifications of
several established protocols. The evening before trans-
fection, cells were plated (typically in six-well dishes) at
a density so that they were at 50 to 80% confluence
when transfected. On the day of transfection, 2 μg DNA
were diluted into 250 μl DMEM without FCS, and an
optimal amount of PEI (usually 2 to 5 μg in water) was
added to the diluted DNA. After 15 minutes of incuba-
tion at room temperature, the mixture was added to
cells dropwise after removal of the conditioned medium,
with swirling of the medium to distribute the reagent.
Immediately afterwards, 2 ml complete medium was
added. Expression of genes was detectable after 12 to 24
hours and was optimal after 24 to 48 hours.
Cells were transfected with Metafectene Pro or Meta-
fectene Easy using the protocol suggested by the manu-
facturer with only minor modifications. Briefly, 2 μg
DNA was mixed with 2.5 μl Metafectene Easy (or 3 μl
Metafectene Pro) prediluted into 50 μl EASY buffer
made from a 10× concentrate diluted with water. After
15 minutes of incubation at room temperature, the lipo-
complexes were added to cells to which 2 ml fresh com-
plete medium was added. Expression was gauged after
48 hours.
Cells were transfected with Fugene (Roche Diagnos-
tics) or with the Amaxa/Lonza Inc. nucleofection system
according to the manufacturers’ instructions.
We used an identical protocol for stable transfection
as for transient transfections in MSCs and B16 cells,
except that on the third day geneticin sulfate (1 mg/ml),
hygromycin sulfate (50 μg/ml for stem cells, 100 μg/ml
for B16 cells), or puromycin sulfate (25 μg/ml) was
added to the complete medium. Selection was continued
until most cells in the population had died (10 days for
G418 and 5 to 7 days for puromycin and hygromycin)
and colonies of antibiotic-resistant cells are seen.
Interferon assays
The titer of Mu-IFNaA released by mMSCs in condi-
tioned medium was gauged by an assay that determines
biologically active interferon, and by an assay that
detects immunoreactive Mu-IFNaA. The anticytopathic
effect inhibition assay (the antiviral assay) was per-
formed on L929 cells as originally described [28]. An
ELISA designed to detect immunoreactive Mu-IFNa
(#42100-1; PBL Interferon Source) was performed
according to the manufacturer’s instructions.
Fluorescence-activated cell sorting
Flow cytometry was performed with a Becton-Dickinson
FACScan (Franklin Lakes, NJ, USA). The FL1 (530/30
nm barrier emission filter) and FL3 (650 long-pass emis-
sion filter) channels were compensated against the FL2
(585/42 barrier emission filter) channel prior to data
collection to minimize the contribution of EGFP fluores-
cence in the FL3 channel and the contribution of ChFP
fluorescence into the FL1 channel. A primary gate on a
forward scatter:side scatter dotplot was used to isolate
intact cells. An inverse gate on an FL1:FL3 dotplot was
applied to mask cells that do not contain significant
levels of GFP or ChFP fluorescence, identified by the
dispersion of cells that were transfected with plasmids
encoding no fluorescent proteins. The ungated cells
(possessing significant GFP-based or ChFP-based fluor-
escence) were then analyzed for their fluorescence. Data
were collected and processed with the CellQuest 3.3
software package (Becton-Dickinson). Histograms and
dotplots were processed with WinMDI2.9 (Joseph Trot-
ter, The Scripps Research Institute, La Jolla, CA, USA)
for presentation in this manuscript.
Mice, stem cell injection and tumor growth monitoring
Two different protocols were used for these experi-
ments. In both cases, C57BL/6 mice (initially from Jack-
son Laboratories for the first experiment, but
subsequently from the National Institutes of Health for
the second experiment) were housed in standard hous-
ing and were nourished liberally. Mice were housed for
7 days prior to the injection of cells.
In the first experiment, B16 melanoma cells (1 million
cells/limb) or PBS carrier were injected subcutaneously
into each hind limb (2 million total cells per mouse) on
day 0. On days 0, 3, and 6, 500,000 MSCs (or PBS car-
rier) were injected into the tail vein of each mouse.
When tumors became palpable at 7 days, one group of
mice was injected at days 7, 10 and 13. The maximum
diameter of each hind limb was measured at days 9 and
13, and the days of death for each mouse were noted.
Statistical analysis of viability curves was performed with
the log-rank test method. Statistical comparisons of
tumor diameters between groups of mice were done
with the unpaired two-tailed p test.
An alternative protocol was used for the second
experiment. Here, 100,000 B16 cells were injected sub-
c u t a n e o u s l yi n t ot h er i g h tf l a n k ;a td a y s0 ,3 ,a n d6 ,
500,000 MSCs were injected into the tail vein of each
mouse (three mice in six groups; one group for each
clonal stem cell line). The growth of each tumor at the
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harboring tumors over 25 mm × 25 mm (lateral tumor
area) were sacrificed. The dorsoventral and rostrocaudal
tumor diameters of surviving mice were measured every
2 to 3 days after the tumor became palpable (after 10 to
20 days).
Results and discussion
Type I interferon secretion by stem cells slows tumor
growth in mice
We first wanted to establish that we could inhibit tumor
growth with MSC-synthesized interferon using our
mouse models. Because IFNb is known to have strong
immunosuppressive activity( h e n c ei t su s ei nt r e a t i n g
multiple sclerosis), and may inhibit an innate anti-tumor
immune response, we chose to instead utilize Mu-
IFNaA to test the effect of a type I interferon more
skewed to anti-tumor activities and less skewed to
immunosuppression. We subcloned the Mu-IFNaA
cDNA from plasmid pLNCX-Mu-IFNaAi n t op l a s m i d
pEF3 [29], and transfected the resultant plasmid pEF3-
MuIFNaA into MSCs. After selection by challenge with
G418, various subclones were tested for their ability to
secrete bioactive Mu-IFNaAb ys c r e e n i n gI F N a secre-
tion by antiviral assay and by ELISA (see below). A
representative clone secreting a high dose of Mu-IFNaA
was amplified and injected into C57Bl/6 mice either
concurrently with B16 melanoma cells (resembling sce-
narios in which tumor development is predicted clini-
c a l l yo rw h e r eap r i m a r yb u tp o t e n t i a l l ym e t a s t a t i c
tumor was excised, and subordinate suppressed tumors
may remain) or after palpable tumors were detected
(modeling a scenario where a tumor is detected but
tumor excision is infeasible or is being avoided), or was
injected in the absence of B16 cells to ensure that these
cells by themselves are not toxic to mice. As controls,
B16 cells were injected in the absence of MSCs to follow
how fast unencumbered tumors grow in mice; B16 cells
were also co-injected with untransfected MSCs to
ensure that the benefit of MSCs requires IFNaA secre-
tion. The results of this experiment are described in
Supplementary Text S3 in Additional file 3 and the data
are shown in Supplementary Figure S1 in Additional file
4. Briefly, while initial growth of tumors is inhibited by
IFNaA secreted by MSCs, suppression of established
tumors by IFNaA was statistically ineffective.
Nevertheless, these results were promising enough to
necessitate developing diagnostic tools to ease the iden-
tification (and perhaps permit noninvasive detection) of
engineered MSCs during cloning and subsequent ther-
apy. We rationalized the development of these tools for
the following reasons. First, there was tremendous clonal
variation in the amount of Mu-IFNaA released within a
transfected population (CDK and LSI, unpublished
observations). Because these cells grew very quickly,
because single-cell suspensions were hard to obtain, and
because our assay systems cannot easily determine
whether all cells in the population express Mu-IFNaA,
we could not easily and conclusively confirm that our
clones were in fact monoclonal. Furthermore, we could
not confirm whether the MSCs we introduced into mice
survived for more than a few days. We do not know
how many stem cells went to each tumor, whether the
MSCs remain there during tumor development, or
whether the engineered MSCs still express Mu-IFNaA.
Additionally, aside from the detecting the gene of inter-
est or the antibiotic resistance element, there is no way
to immunologically or histologically distinguish engi-
neered MSCs from MSCs that endogenously reside
within the host, especially under therapeutic scenarios.
To address these issues we needed transfected cells
that express not only Mu-IFNaA but also the mono-
meric ChFP, which folds quickly and emits red light
upon illumination with blue or especially green or
orange light. There are several ways to co-express two
proteins ectopically in cells. Co-transfection of two dis-
tinct plasmids does not give a reliable indicator of
IFNaA secretion given an amount ChFP fluorescence,
especially from clone to clone of a transfected popula-
tion (CDK, unpublished observations). Fusion of the two
transcription units into a single plasmid to create a tan-
dem vector did not improve this relation. The easiest
way to assure the equivalent transcription of both ORFs,
such that both ORFs are transcribed if the translation of
one of the two ORFs is demonstrated, was to separate
the two ORFs with an IRES.
Construction of a bicistronic vector to monitor the
expression level of a transgene
Our first construction placed the Mu-IFNaAc D N A
after the elongation factor-1a (EF1A) promoter and
placed the ChFP cDNA after the IRES encoded by the
encephalomyocarditis virus (EMCV) genome, so that
translation of Mu-IFNaA is cap-dependent while trans-
lation of ChFP is IRES-dependent. We observed that,
when expressed as a monocistronic message (from plas-
mid pEF3-ChFP; Figure 2a,b left), translation of the
ChFP was about 30-fold stronger than in our first bicis-
tronic plasmid pEF3-MuIFNaAEMCV*ChFP (Figure 2a,
b second from left).
Sequence analysis revealed that this EMCV IRES was
mutated and its efficiency inhibited by sevenfold to 10-
fold (Figure 2). This mutation eliminated a KpnIs i t e
within the IRES that lies along an important secondary
structure element [30-33]. We instead used a sequence
that more closely resembled the wildtype viral genome
sequence (only differing in the mutation of an ApaLI
site and the deletion of one A in a seven-A stretch, both
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EMCV IRES (to create plasmid pEF3-MuIF-
NaAEMCVChFP), the translation of ChFP was much
more efficient (about 16 to 20% that of the monocistro-
nic message; Figure 2a,b middle).
We wanted to test an IRES of cellular origin that is
resistant to inhibition of cap-dependent protein synth-
esis [34-37] or interferon effects [38] - that from the c-
myc P2 mRNA [39,40]. c-Myc-dependent ChFP transla-
tion in plasmid pEF3-MuIFNaAcmycChFP, however,
was poor (about 5%; Figure 2a,b second from right).
Additionally, we found that translation of the c-myc
IRES-dependent cistron was not uniform with respect to
the translation of EGFP (Figure 2a right); this was
explained by the known ability of the c-myc IRES to
allow translation under conditions when cap-dependent
protein synthesis is inhibited, such as mitosis (Supple-
m e n t a r yF i g u r eS 2 ,l e f ti nA dditional file 5), genotoxic
stress or apoptosis (Supplementary Figure S2, right in
Additional file 5) [35,41]. Because of these peculiarities
and because the EMCV IRES was more well defined
structurally and produced sufficient levels of ChFP for
our purposes, we restricted our subsequent work to the
optimal EMCV IRES.
Irrespective of which IRES was used, translation of
ChFP from the first cistron was about 65 to 70% as effi-
c i e n ta st h a tt r a n s l a t e df r o mam o n o c i s t r o n i cm e s s a g e
(Figure 2c, compare the rightmost three lanes), or about
Figure 2 Translation of cistrons from pEF3-based plasmids. (a) 293T cells were transfected using polyethyleneimine (PEI) with the following
plasmids (from left to right): pEF3-ChFP, pEF3-MuIFNaAEMCV*ChFP, pEF3-MuIFNaAEMCVChFP, pEF3-MuIFNaAcmycChFP, and pEF3-
ChFPcmycEGFP. The monomeric cherry fluorescent protein (ChFP)-expressing cells were resolved from nonfluorescent cells (isolated by the black
gate labeled R2) by a contoured dotplot of FL1 (EGFP levels, horizontal) versus FL3 (ChFP levels, vertical) fluorescence. (b) Histograms of FL3
fluorescence of the ungated population (red) and the inversely-gated population indicating the ChFP-positive cells (light red, overlaid) are placed
under the respective contour plots. (c) Comparison of ChFP translation rates. The mean red fluorescence of the inversely gated cells are shown
for cells transfected with the following plasmids (from left to right): no ChFP cistron (pEF3-MuIFNaA, pEF3-EGFP), ChFP as the second cistron
(pEF3-MuIFNaAEMCV*ChFP, MuIFNaAcmycChFP, pEF3-MuIFNaAEMCVChFP, pEF3-EGFPEMCVChFP), ChFP as the first cistron (pEF3-
ChFPEMCVEGFP, pEF3-ChFPcmycEGFP), and ChFP as the only cistron (pEF3-ChFP).
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IRES-controlled cistron (Figure 2c, compare lanes 5 to 7).
Although we know the both the IRES-dependent and
the cap-dependent cistrons are translated in our vector
system (Figure 1), we wanted to prove that bioactive Mu-
IFNaA was produced in our bicistronic system. To prove
IFNaA was translated and secreted in an active form,
plasmids pEF3-IFNaAEMCV*ChFP, pEF3-IFNaAc-
mycChFP and pEF3-IFNaAEMCVChFP were stably
transfected in MSCs and several clonal cell lines from
each population were isolated that demonstrated signifi-
cant red fluorescence (it is more economical and faster to
i s o l a t ec l o n e sb yf l u o r e s c e n c et h a nb yi n t e r f e r o nb i o a s -
say). Conditioned medium (2 ml medium collected after
2 days) from these monoclonal cell lines as well as from
several MSC monoclonal cell lines expressing plasmid
pEF3-MuIFNaA (one of which was used in Supplemen-
tary Figure S1 in Additional file 4) all possessed bioactive
IFNa (Figure 3a). Notably, conditioned medium from
MSCs expressing Mu-IFNaA as the only cistron con-
tained generally fivefold to eightfold more bioactive inter-
f e r o nt h a nd i dc o n d i t i o n e dm e d i u mf r o mM S C s
transfected with plasmids expressing bicistronic mes-
sages. Conditioned medium from MSC clones stably
transfected with plasmids pEF3-IFNaAEMCV*ChFP and
pEF3-IFNaAcmycChFP were tested by ELISA; all clones
were found to produce protein that was immunoreactive
with serum raised against murine IFNa (Figure 3b). To
prove that the IFNaA released from these cell lines was
completely active, we calculated the specific activity of
the interferon by dividing the bioactivity by the immuno-
concentration for the 12 clones. Ignoring clones that
poorly express Mu-IFNaA (usually resulting in weak
antiviral activity in conditioned medium), the clones
secrete Mu-IFNaA with a specific activity of 2 × 10
7 to 8
×1 0
7 units/mg, in good agreement with the published
value of purified bacterial recombinant Mu-IFNaA( 5×
10
7 to 10 × 10
7 units/mg). We therefore conclude that
fully bioactive Mu-IFNaA is released by these MSCs
transfected with these vectors, and that both cistrons are
translated.
Proving that both cistrons are expressed in our bicis-
tronic plasmids, and that the first cistron is translated
about three to 3.5 times better than the second cistron
on a population level, we next sought to determine
whether this difference in cistron expression applies to
all cells in the population. To address this, we placed
the EGFP cDNA after the EF1A promoter, and then
made a construct in which we exchanged the places of
ChFP and EGFP, creating plasmids pEF3-EGF-
PEMCVChFP and pEF3-ChFPEMCVEGFP. As shown
in Figure 4a, while cells expressing either pEF3-ChFP
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Figure 3 Bioactivity of Mu-IFNaA translated from bicistronic vectors. In conditioned medium from mesenchymal stem cell (MSC) clones
where both bioactivity and immunoreactivity were measured, the specific activity of interferon in each medium was calculated and each clone
was separately color-coded. In all cases, the activity was determined by comparison with a standard murine interferon, produced in Escherichia
coli and purified to homogeneity, and the mean of each group of values are shown with a horizontal line. (a) Left: conditioned medium from six
monoclonal MSC lines stably transfected with (from left to right) pEF3-MuIFNaA, pEF3-MuIFNaAEMCV*ChFP and pEF3-MuIFNaAcmycChFP were
assayed for bioactivity by the antiviral assay. Right: in a separate experiment, conditioned medium from 12 monoclonal MSC lines stably
transfected with pEF3-MuIFNaA and from four monoclonal MSC lines stably transfected with pEF3-MuIFNaAEMCVChFP were assayed. (b)
Conditioned medium from six monoclonal MSC lines stably transfected with pEF3-MuIFNaAEMCV*ChFP (left) and pEF3-MuIFNaAcmycChFP
(right) were assayed for Mu-IFNa immunoconcentration by ELISA. (c) Specific activities of the Mu-IFNaA within each conditioned medium were
calculated by dividing the bioactivity by the immunoconcentration. Bacterial recombinant Mu-IFNaA purified to homogeneity has a specific
activity of 5 × 10
7 to 10 × 10
7 units/mg; this range is indicated with the brackets between the two datasets. ChFP, monomeric cherry
fluorescent protein.
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Page 9 of 20or pEF3-EGFP express only one fluorescent protein
and (after compensation of the green and red chan-
nels) have little color in the other channel, cells
expressing plasmids pEF3-EGFPEMCVChFP and pEF3-
ChFPEMCVEGFP exhibited both red and green
fluorescence.
After translating various FL1:FL3 dotplots so that
untransfected cells optimally overlap, the cells with
brighter EGFP and ChFP fluorescence lie along parallel
distributions in the overlaid dotplots (diagonal lines, Fig-
ure 4). Because these dotplots are double-logarithmic
plots, parallel lines infer proportional expression of the
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Figure 4 Efficiency of cap-dependent versus internal ribosome entry site-dependent translation in various cell lines. Plasmids pEF3-
ChFP (in red), pEF3-EGFP (in green), pEF3-EGFPEMCVChFP (in black) and pEF3-ChFPEMCVEGFP (in brown) were transfected into (a) 293T cells, (b)
B16 cells and (c) mesenchymal stem cells (MSCs). Contour plots of FL1 (EGFP levels) versus FL3 (monomeric cherry fluorescent protein (ChFP)
levels) were made of the green and red fluorescence from a sample of cells in each population. Lines were drawn through the medians of the
cells demonstrating strong EGFP and ChFP fluorescence. (d) Because insufficient numbers of cells with strong fluorescence could be obtained in
MSCs transfected with these plasmids, plasmids pmaxCDK-EGFPEMCVChFP (black) and pmaxCDK-ChFPEMCVEGFP (brown) were transfected into
MSCs. Each population was translated in the dotplot so that the populations of nonfluorescent cells optimally overlapped.
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siderably throughout the population. The axial distance
between the two parallel lines denotes the difference in
the expression of one cistron if the expression of the
other cistron is constant, and defines the difference in
efficiency of translation between the cap and the IRES
in bicistronic messages. In both 293T cells (Figure 4a)
and in B16 melanoma cells (Figure 4b), cap-dependent
translation was about threefold more efficient than
IRES-dependent translation using pEF3-based plasmids.
This ratio correlated with the data from Figure 2c. We
could not obtain a definitive number in MSCs using
these plasmids (Figure 4c), mostly because these plas-
mids were poorly transfected( s e eb e l o w ) .T h ea b o v e -
observed threefold difference, however, is also seen in
MSCs when an optimal vector system was used (Figure
4d). Our data therefore suggest that the efficiency of
IRES-dependent translation does not vary significantly
among cell lines.
Variation of transfection efficiency is vector-dependent
As we mentioned above, the transfection efficiency of
our pEF3-based plasmids was rather poor in MSCs. In
contrast, plasmid pmaxGFP (supplied as a positive con-
trol in the Amaxa/Lonza Inc. nucleofection kit) trans-
fected only slightly better than our pEF3-based plasmids
in 293T cells (Figure 5, left), but transfected more effi-
ciently than pEF3-based plasmids in B16 cells (Figure 5,
middle), and considerably better than our pEF3-based
plasmids in MSCs (Figure 5, right). For reasons we do
not understand, the transfection efficiency of plasmid
pmaxGFP decreased less drastically in MSCs (from 55
to 60% down to 24%) relative to other cell lines than
did the transfection efficiency of pEF3-based plasmids
(from 43% down to 4%). This difference in transfection
efficiency was not greatly affected by the transfection
reagent whether less expensive reagents like PEI or
Metafectene or more expensive optimized systems like
the Amaxa/Lonza Inc. nucleofection system were used
to warrant further use of expensive reagents. We there-
fore focused our studies with PEI, the reagent of choice
with 293T and B16 cells, or with Metafectene Easy, the
reagent of choice with MSCs and B16 cells.
To determine why pEF3-based plasmids transfected
much more poorly than pmaxGFP in MSCs, we
wanted to exchange various parts of pEF3 to optimize
its expression, as the sequence of pmaxGFP is not
publically available. Like most other expression vec-
tors, however, pEF3-based plasmids only have useful
restriction sites within the multicloning site that lie
after the promoter that is driving expression of the
GOI. Because few useful sites lie outside this region,
exchanging antibiotic elements, promoters or untrans-
lated regions to optimize the plasmid poses a problem.
To overcome this problem, we mutated plasmid
pcDNA3 (a well-defined and validated plasmid from
which plasmid pEF3 derived [42]) so that one can
easily exchange the promoter driving the GOI, the
polyadenylation site for the GOI, the promoter driving
t h ea n t i b i o t i cr e s i s t a n c eg e n e ,t h er e s i s t a n c eg e n e
itself, and the polyadenylati o ns i t ef o rt h ea n t i b i o t i c
resistance gene. The method by which we mutated
pcDNA3 to make pc3.5 was described in Materials
and methods. After making this plasmid, we noticed
that, outside the antibiotic resistance gene, the BssHII,
NaeI (both before the SV40 promoter) and PvuII
(after the SV40 polyadenylation site) sites are unique
and can also be used for cloning if necessary. In fact,
exchanging the neomycin resistance gene for that of
hygromycin and (by virtue of a fortuitous mutation
obtained during PCR amplification) puromycin made
these three sites unique. From plasmid pc3.5 we made
a variety of vectors to test which elements promote
efficient expression in MSCs and easily produce stably
transfected clonal cell lines; these vectors are shown
schematically in Figure 1.
Modification of the eukaryotic antibiotic resistance gene
Our first hypothesis was that elements within the anti-
biotic resistance gene inhibited optimal expression of
our bicistronic vector, as plasmid pmaxGFP has no
eukaryotic resistance gene. In plasmid pc3.5, the SV40
promoter drives expression of the neomycin resistance
gene; the SV40 polyadenylation site follows the neomy-
cin resistance gene. We exchanged the SV40 promoter
for the phosphoglycerate kinase-1 (PGK-1) promoter
(driving the hygromycin resistance gene), replaced the
neomycin resistance gene with the puromycin resistance
gene, and utilized the PGK-1 polyadenylation site
instead of the SV40 polyadenylation site to create plas-
mids pc3.5PGKhygro, pc3.5puro, and pc3.5neoPGK,
respectively. We also exchanged all three elements to
make plasmid pc3.5PGKpuroPGK. After placing three
bicistronic GOIs (MuIFNaAEMCVChFP, EGF-
PEMCVChFP, and ChFPEMCVEGFP) under the control
of a fully active 5’ truncated EF3 promoter (Figure 6,
top) in an intermediate plasmid, we recombined the
EF3-driven GOIs with the pc3.5-derived plasmids with
the modified antibiotic resistance genes. This resulted in
plasmids pEF3.5bPGKhygro-(GOI), pEF3.5puro-(GOI),
pEF3.5bneoPGK-(GOI), and plasmid pEF3.5bPGKpur-
oPGK-(GOI), as described in Materials and methods.
Only the results for the bicistron EGFPEMCVChFP are
shown.
We found that, except for the plasmids based on
pc3.5puro, the expression of the GOIs did not vary
among the plasmids in 293T cells (Figure 6, bottom
left), implying that the elements controlling the
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expression of the GOI. Additionally, these changes did
not improve the expression of pEF3.5b-based plasmids
compared with pmaxGFP in either B16 cells (Figure 6,
bottom middle), and may slightly inhibit the expression
of the GOI in MSCs (Figure 6, bottom right). No
exchange improved the transfection of pEF3.5b-based
plasmids to that seen with pmaxGFP. Notably, the
slightly improved expression of the GOI in the pEF3.5b-
puro plasmid required the SV40 promoter and/or the
SV40 polyadenylation site, as exchange of the SV40 ele-
ments for those of PGK1 to control the expression of
the puromycin gene reduced the expression of the GOI.
Nevertheless, we used hygromycin or puromycin in
MSCs to more quickly select for resistant cell lines har-
boring the GOI and successfully amplify monoclonal
MSC cell lines (data not shown). We therefore conclude
that these elements could easily be exchanged to make
plasmids with new properties that do not inhibit their
ability to be transfected.
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Figure 5 Transfection efficiency of pEF3-based plasmids in 293T, B16 and mesenchymal stem cells. Plasmids pEF3-MuIFNaAEMCVChFP,
pEF3-EGFPEMCVChFP, pEF3-ChFPEMCVEGFP, and pmaxGFP were transfected (left) into 293T cells using polyethyleneimine, (middle) into B16 cells
using Metafectene Easy and (right) into mesenchymal stem cells (MSCs) using Metafectene Easy. The percentage of cells containing significant
levels of GFP and/or monomeric cherry fluorescent protein (ChFP) as well as the average green or red fluorescence of these cells were
determined. These values were then divided by the related values determined in cells transfected with pEF3-EGFPEMCVChFP, whose actual
transfection efficiency (as well as that from pmaxGFP) is shown above the bars. Relative transfection efficiency and relative average fluorescence
intensity are indicated by black and grey bars, respectively. The results shown here are representative; the transfection efficiency as well as the
relative expression or transfection difference between pEF3-based plasmids and pmaxGFP varied by as much as twofold depending on
transfection reagent, passaging time, and cell density.
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expression of the mRNA of the GOI
We next hypothesized that elements controlling the
expression of the GOI strongly influence the transfection
efficiency of the resulting plasmid. We chose not to alter
the polyadenylation sequences controlling the GOI
because the bovine growth hormone polyadenylation
sequence is already known to generate stable mRNA
molecules and therefore promotes maximal expression of
the GOI. Suspecting that the human EF1A promoter may
not work well in these MSCs, we tried other promoters or
implemented synthetic introns to more efficiently drive
the GOI. First, we exchanged the CMV promoter in
pc3.5hygro and pc3.5puro for the PGK-1 promoter, a pro-
moter of similar strength but of cellular origin [43-46], to
create plasmids pPGK1.5hygro and pPGK1.5puro.
The expression of a GOI is enhanced when introns
are transcribed with the exons of a protein-coding RNA;
Figure 6 Transfection efficiency of pEF3.5b-based plasmids harboring varying antibiotic resistance genetic elements. Top: synthesis of
truncated elongation factor-1a (EF1A) promoters. From the full-length EF1A promoter found in plasmid pcDEF3 [42], various truncations were
performed to shorten the promoter without sacrificing activity. The uppermost truncation eliminates an unnecessary piece of the intron [50].
Truncations at the 5’ end of the promoter to remove fragments derived from other vectors created vectors pEF3.5, pEF3.5a and pEF3.5b; only
pEF3.5b expressed proteins as well as plasmids pEF3 and pcDEF3 (data not shown). Useful restriction sites within the promoter are shown.
Truncations are shown with broken lines, and the amount of promoter upstream of the SacII site is shown. The direction of each element in
pcDEF3 is shown in the topmost schematic. Bottom: vectors pEF3, pEF3.5bPGKhygro, pEF3.5bpuro, pEF3.5bneoPGK, and pEF3.5bPGKpuroPGK, all
harboring and expressing the bicistronic insert EGFPEMCVChFP, were transfected using polyethyleneimine into (left) 293T cells, (middle) B16 cells,
and (right) mesenchymal stem cells (MSCs), and the percentage of successful EGFP expression (black bars) as well as the average fluorescence of
the EGFP-expressing cells (gray bars) were reported as a percentage of that seen in cells transfected with pEF3-EGFPEMCVChFP. In B16 cells and
in MSCs, plasmid pmaxGFP was also transfected to determine whether improved transfection in these cells was obtained. The actual percentage
of transfection of pEF3-EGFPEMCVChFP and pmaxGFP is shown above their respective bars.
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effectively coupled to the mRNA export machinery than
are nascent RNAs that do not contain introns [47-49].
Indeed, the EF1A and polyubiquitin promoters are six-
fold more active if the first intron within the 5’ UTR is
present [50,51]. We employed the mRNA export path-
w a yb yp l a c i n gas y n t h e t i ca n dc h i m e r i ci n t r o n( c o m -
posed of a b-globin splice site donor and an IgG splice
site acceptor) within the 5’ UTR between an intronless
cDNA and either the CMV or the PGK promoters to
make plasmids pCMVi.5hygro, pCMVi.5puro, pPGKi.5-
hygro and pPGKi.5puro. Finally, we tested a promoter
(the human COX-2 promoter) that is inducible by
inflammatory signals [52] and could further restrict the
secretion of interferons to those MSCs that sense
inflammatory signals, such as often found within
tumors.
We found that the better transfection efficiency corre-
lated with stronger average expression (Figure 7). This
was true whether 293T cells (left), B16 cells (middle) or
MSCs (right) were used, suggesting that both high trans-
fection efficiency and good protein expression per cell
are proportional to promoter strength. The CMV pro-
moter with intron, whether in pc3.5-based plasmids or
in pmax-based plasmids (Figure 7, with asterisk), gener-
ally gave both the highest expression and the highest
transfection efficiency (between 150 and 250% that of
pEF3-based plasmids). The synthetic intron, known to
boost the activity of the CMV and SV40 promoters by
up to eightfold in diverse studies, probably underlies the
complementation of the sevenfold weakness of the CMV
promoter relative to the EF1A promoter in our plasmid
system. PGK promoters with included introns had activ-
ities comparable with those of EF1A promoters
(between 70 and 130% that of pEF3-based plasmids).
PGK-1 promoters without introns were one-half as
strong as those with chimeric introns (with activities
approximating 50 to 70% those of pEF3-based plasmids).
The weakest of these promoters was the cyclooxygen-
ase-2 promoter, with activities 15 to 40% those of EF3-
based plasmids. The difference in promoters was less
apparent in 293T cells than in B16 cells and in MSCs.
Because we found that expression of our GOIs was lar-
gely equivalent under the CMV-intron promoter
whether the backbone vector was pc3.5-based or
whether it was pmaxGFP-based (Figure 7), we con-
cluded that use of a sufficiently strong promoter is suffi-
cient to enhance the expression of target genes in
MSCs.
Expression of GFP from pmaxGFP was still better in
most cases than expression of our GOIs, however, even
when using the same vector and the same plasmid back-
bone. The GFPs used in our bicistronic vectors were
designed to be nonaggregating and monomeric [53,54],
whereas the primary sequence of GFP used in pmaxGFP
closely resembles the wildtype aggregating GFP from the
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Figure 7 Transfection efficiency of various pc3.5-based vectors harboring promoters and/or introns controlling the gene of interest.
Plasmids pEF3, pCOX2.5, pPGK1.5puro, pPGKi.5puro, pEF3.5bpuro, pCMVi.5puro, and pmaxCDK harboring the bicistronic insert EGFPEMCVChFP
were expressed in (left) 293T cells, (middle) B16 cells and (right) mesenchymal stem cells (MSCs). These harbor the following promoters and/or
introns: cyclooxygenase (COX)-2, phosphoglycerate kinase (PGK)-1, PGK-1 with b-globin/IgG chimeric intron, EF3.5b, cytomegalovirus (CMV) with
b-globin/IgG chimeric intron, and CMV with b-globin/IgG chimeric intron. The asterisk implies expression of the insert from plasmid pmaxCDK
instead of from plasmid pCMVi.5puro. Black bars, relative transfection efficiency compared with cells transfected with pEF3-EGFPEMCVChFP; grey
bars, relative EGFP levels compared with cells transfected with pEF3-EGFPEMCVChFP. Plasmid pmaxGFP was also transfected to determine
whether improved transfection in MSCs was obtained. Expression from the COX-2 promoter was insignificant and therefore not shown in B16
cells and in MSCs.
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ciently stable that they are toxic to cells. To test
whether use of a nonaggregating mutant of this GFP
modified the apparent expression efficiency of
pmaxGFP, we substituted the wildtype GFP in plasmid
pmaxGFP with its nonaggregating (but dimeric) mutant
called TurboGFP [55] to create pmaxCDK-TurboGFP,
and compared the expression of pmaxGFP with that of
pmaxCDK-TurboGFP. We found that there was better
transfection efficiency and overall expression of GFP
from pmaxGFP than from pmaxCDK-TurboGFP, irre-
spective of transfection protocol or whether 293T cells,
MSCs or B16 cells were used (Supplementary Figure S3
in Additional file 6).
Auto-inhibitory actions of Mu-IFNaA on its own
expression
We next wanted to understand why transfection of
bicistronic messages encoding Mu-IFNaAw a sl e s se f f i -
cient than those that do not encode Mu-IFNaAi n
murine (B16, MSC) cells but not in human (293T)
cells (Figure 5). Because type I interferons are known
to inhibit translation in a species-specific fashion, and
because we suspected that lowered expression of pro-
teins resulted in lower apparent transfection efficien-
cies, we hypothesized that the activity of murine type I
interferon inhibits the expression and therefore the
apparent transfection efficiency of plasmids encoding
Mu-IFNaA in murine cells. To test this, and to test
whether interferons differentially inhibit cap-dependent
or EMCV IRES-dependent translation in our system,
we transfected pmaxCDK-ChFPEMCVEGFP into B16
cells and MSCs and treated them with 500 units/ml
Mu-IFNaA or with PBS alone. In both cell lines, both
the transfection efficiency and the levels of EGFP
decreased by 10 to 15% (Figure 8a). Co-transfection of
pmaxCDK-ChFPEMCVEGFP with pEF3-MuIFNaA
gave a slightly higher inhibition of transfection effi-
ciency as well as decreased levels of fluorescent cells
(data not shown). A comparison of the dispersion of
fluorescent cells in the absence or presence of inter-
feron demonstrated that there was a complete overlap
in both cell lines (Figure 8b, black dots and red dots,
respectively), implying that inhibition of expression did
not favor cap-dependent over IRES-dependent transla-
tion. Conversely, treatment of B16 cells transfected
with plasmid pCMVi.5puro-MuIFNaAEMCVChFP
with neutralizing monoclonal antibodies specific to
murine IFNa increased the apparent transfection effi-
ciency as well as the mean ChFP levels by 10 to 15%
(Supplementary Figure S4 in Additional file 7). This is
consistent with the hypothesis that the presence of
type I interferon in the medium inhibits transfection
efficiency or expression levels. The transfection
efficiency of this plasmid in MSCs was too poor for
useful analysis to be done, even in the presence of
monoclonal antibodies (data not shown).
Dosage-dependent effects of MSC-synthesized Mu-IFNaA
within B16 tumors in mice
Using derivatives of plasmid pc3.5, we created a panel of
MSC lines with a wide variety of Mu-IFNaA secretion
rates. These clones can be used to produce a dose-
response curve in vivo to determine whether maximal
IFNa release is optimal or instead is detrimental to
anti-tumor responses. We chose five of these clones
(with secretion rates of 200, 2,000 to 5,000, 18,000 to
25,000, 62,500, and 175,000 units/million cells/day -
referred to here as MSC/a, MSC/b, MSC/c, MSC/d and
MSC/e, respectively) to inject into the tail vein of
C57Bl/6 mice injected subcutaneously in the right flank
with 100,000 B16 cells. Tumor growth was monitored
for 5 weeks and the rostrocaudal and dorsoventral
tumor diameters were measured on days 27, 29, 32, 34,
and 36 (depth diameter was assumed to be the mean of
the other two diameters). The details of this experiment
are described in Supplementary Text S3 in Additional
file 3. Briefly, higher interferon doses inhibited initial
tumor growth but actually promoted faster tumor
growth, while lower doses of interferon within tumors
did not prevent the initial growth of tumors but slowed
their overall growth rate (Supplementary Figure S5 in
Additional file 8).
Conclusions
The use of adult-derived stem cells such as MSCs to
modify the growth or properties of tissues is an active
area of biomedical research. Expressing heterologous
genes from MSCs will greatly expand the potential of
MSCs in disease treatment. There is a bewildering vari-
ety of plasmids available for use, but generally each plas-
mid was designed for a particular purpose. Because the
delivery of a given therapeutic should be controllable
physiologically, an optimal vector for use in stem cell
t h e r a p ys h o u l da l l o wo n et oe a s i l ye x c h a n g ev a r i o u s
genetic elements to suit physiological needs. In the pre-
sent manuscript we introduce a vector as well as a series
of derivatives that are based on the well-validated plas-
mid pcDNA3. By inserting a few point mutations that
insert useful restriction endonuclease sites, this plasmid
(pc3.5) allows easy exchange of promoters and polyade-
nylation sequences controlling either the gene of interest
or the antibiotic resistance gene, as well as the antibiotic
resistance gene itself. Each of the derivative plasmids we
synthesized resulted in both transient and stable expres-
sion of the GOI. The transfection efficiency as well as
expression from these vectors is comparable to that
seen for the most popular or effective vectors currently
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engineered cells more efficiently than do plasmid vectors
- can be similarly modified with a few nucleotide substi-
tutions at borders between genetic elements to produce
multifaceted viral vectors.H o w e v e r ,e a c hv a r i a n to fa
viral vector needs to be tested for viral packaging, infec-
tivity and biosafety, which is a hindrance relative to
plasmid-based vectors.
To visualize MSCs that express type I interferons, we
constructed a bicistronic message in which the Mu-
IFNaA cDNA is the first cistron while the ChFP cDNA
is second cistron, whose translation was driven by the
IRES from the EMCV genome. We ran into issues, how-
ever, trying to express this bicistronic message efficiently
in MSCs using our initial vector pEF3. These issues
were particularly obvious when comparing its expression
Figure 8 Inhibition of transfection and expression by type I interferons in B16 and mesenchymal stem cells. (a) B16 cells (left) and
mesenchymal stem cells (MSCs) (right) were transfected with pmaxCDK-ChFPEMCVEGFP and were either not treated (black bar) or treated (grey
bar) with 500 units/ml Mu-IFNaA. Top: bar graph depicting the transfection efficiency. Bottom: bar graph depicting the mean EGFP levels. (b)
Contour plot of EGFP levels (horizontal axis) versus monomeric cherry fluorescent protein (ChFP) levels (vertical axis) in B16 cells (top) and in
MSC cells (bottom). Cells not treated with Mu-IFNaA are black; cells treated with Mu-IFNaA are red.
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the Amaxa/Lonza Inc. nucleofection kit (Figures 5 to 7).
Considerable improvements in the expression of bicis-
tronic messages were discovered while resolving this
issue. Although some improvement in the expression of
the GOI came from modifying the expressing the puro-
mycin instead of hygromycin or neomycin/geneticin)
resistance genes (Figure 6), a greater improvement came
from utilizing a stronger promoter and employing a chi-
meric 5’ intron (Figure 7).
During the optimization process, we placed this bicis-
tronic cDNA into a series of vectors expressing various
promoters or eukaryotic antibiotic resistance genes (Fig-
ure 1). We successfully isolated clonal MSC lines from
populations transfected with nearly all of these vectors.
In these clonal cell lines, the cherry fluorescence of
these cells was proportional to the rate of secretion of
bioactive Mu-IFNaAf r o mt h e s ec e l ll i n e s( d a t an o t
shown). Not surprisingly, Mu-IFNaA secretion was gen-
erally weaker from clones expressing bicistronic mes-
sages than from clones expressing only Mu-IFNaA. In
most clones secreting more than 5,000 units of inter-
feron per 1 million cells per day, however, the specific
activity of the released Mu-IFNaA in the conditioned
medium ranged from 3 × 10
7 to 8 × 10
7 units/mg
whether the (intron-truncated) EF1A promoter, the 5’
trimmed EF1A promoter, or the PGK-intron promoter
was used to express the bicistronic cDNA (data not
shown).
We noticed that the bicistronic MuIFNaAEMCVChFP
message transfected more poorly than the bicistronic
EGFPEMCVChFP message in B16 cells and especially in
MSCs (Figure 6). We believe this inhibition is due to a
species-specific autocrine signaling loop of the synthe-
sized Mu-IFNaAw i t ht h em u r i n eI F N a receptor pre-
sent in murine MSCs. This is supported by the
following observations: the inhibition of transfection or
expression is not observed in human 293T cells (Figure
5); exogenous addition of Mu-IFNaA to B16 cells trans-
fected with bicistronic messages slightly inhibited the
transfection or expression of bicistronic messages that
do not encode Mu-IFNaA (Figure 8); and the addition
of neutralizing antibodies raised against Mu-IFNa
slightly enhanced the expression of bicistronic messages
encoding Mu-IFNaA in murine cells (Supplementary
Figure S4 in Additional file 7). Notably, inhibition or
enhancement of expression with exogenous treatment
was not as effective as the decrease seen when Mu-
IFNaA is expressed directly. Because vector-derived
Mu-IFNaA is synthesized luminally prior to its secre-
tion, while our Mu-IFNaA and monoclonal antibody
treatments were extracellular, our failure to fully restore
or inhibit the translation of various bicistronic messages
could be explained by intraluminal signaling by high
concentrations of newly-synthesized type I interferon
within secretory vesicles. Hypothesizing that luminal sig-
naling of newly synthesized type I interferons in MSCs
greatly affects the expression of Mu-IFNaA-containing
messages, this inhibition may be offset by inhibiting the
expression or activity of type I interferon receptor
though which Mu-IFNaA signals.
Related to this were issues with isolating clonal MSC
lines expressing MuIFNaAEMCVChFP; these clones
often grew slower than untransfected MSCs and were
diluted out during the selection process and expansion
of surviving clones. This is exemplified in Supplemen-
tary Figure S6 in Additional File 9, in which stably
transfected cells expressing the bicistronic message
MuIFNaAEMCVChFP only divided a few times relative
to its neighbors that did not express this message (Sup-
plementary Figure S6, top). By comparison, stably trans-
fected MSCs expressing EGFPEMCVChFP
(Supplementary Figure S6, middle in Additional file 9)
and expressing TurboGFP from a monocistronic mes-
sage (Supplementary Figure S6, bottom in Additional
file 9) divided quickly, at a rate comparable with that for
untransfected cells. Nevertheless, these stably transfected
MSC lines appear to divide and have morphology
resembling parental MSCs.
Paradoxically, higher doses of interferon within
tumors prevented initial growth but accelerated the
tumor growth rate (Supplementary Figure S5 in Addi-
tional file 8). This is rationalized based on the known
anti-angiogenic activities of type I interferon [15], as
angiogenesis is a prerequisite for tumor growth. Perhaps
interferon should be present in higher doses during the
establishment of tumors but be present only at lower
doses once a tumor has been established. In agreement
with this, it has been observed that cells chronically
exposed to IFNa eventually lose sensitivity to IFNa
[56]. Perhaps the high dosages of IFN are desensitizing
tumors cells in a similar way, removing its beneficial
effects, and the accelerated tumor growth rate is simply
a less inhibited tumor doubling rate. If so, then use of
an interferon with less potency - such as human IFNa1
[57,58] or type III interferon [11,56,59] - may be useful
in the treatment of established epithelial tumors. The
failure of IFNaA to inhibit tumor growth in our mouse
models reinforces a need to consider alternate biothera-
peutic strategies, such as TNFa or IL-24 that are known
to have anti-angiogenic properties [60]. They could be
used instead of IFNa or (with a second IRES) in addi-
tion to IFNa. Also, because certain therapeutics may be
more effective against certain types of tumors and less
effective in others, use of other tumor models or alter-
nate strains of mice could help define the spectrum of
effectiveness of various anti-tumor therapeutics. Finally,
because each anti-tumor therapeutic may act by distinct
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tein components (that is, recombinant immune recep-
tors, immunocyte enzymes, cytokine receptors) can help
delineate how each therapeutic exhibits its activity. Co-
culture systems can also be used to investigate the
molecular details of various anti-tumor mechanisms.
Further studies are planned to utilize alternate therapeu-
tics, alternate tumor models and alternate strains of
wildtype or mutant mice.
Overall, we successfully used pc3.5-based plasmids
and their derivatives to optimize both transient and
stable transfections of plasmids in a variety of cell lines.
We can easily exchange antibiotic resistance elements as
well as mRNA-controlling elements. This plasmid family
has been used for a variety of other purposes beyond
the scope of the present manuscript. These plasmids
can be used, coupled with an IRES, to make MSCs cap-
able of being fluorescent and simultaneously secreting
type I interferon, whose inhibitory effects on tumor
growth may be at least partially distinct from its effects
on inhibiting tumor establishment. These engineered
MSCs can be visualized, and in this way are easily dis-
tinguished from parental or endogenous MSCs, and will
help provide a real-time readout of the efficiency of
engineered MSCs within tumors.
Additional material
Additional file 1: Supplementary Text S1: Supplementary text with
references. Adobe PDF file containing information about how various
PCR products were amplified.
Additional file 2: Supplementary Text S2: Supplementary text with
references. Adobe PDF file containing information about how various
plasmids were synthesized.
Additional file 3: Supplementary Text S3: Supplementary text with
references. Adobe PDF file containing text describing the two mouse
experiments.
Additional file 4: Supplementary Figure S1: The initial mouse
experiment. Adobe PDF file detailing the first mouse experiment. Reduced
growth of tumors by MSCs ectopically expressing Mu-IFNaA. Plasmid pEF3-
MuIFNaA was stably transfected into MSCs and a representative clone
known to release high levels of fully bioactive Mu-IFNaA was amplified (MSC/
IFNa). Fifteen mice were subdivided into five experimental groups of three
mice each: in three mice, only B16 cells were injected (black); in three mice,
B16 cells and parental MSCs were injected (red); three mice received B16 cells
and MSC/IFNa cells (green); the next group of three mice received MSC/IFNa
only after tumors derived from B16 cells were palpable, starting at day 7
(blue); the final three mice received only MSC/IFNa cells (purple). The dates
of injection of B16 cells (black arrow) and of MSCs (green and blue arrows for
zero and seven day injections, respectively) are labeled. (a) The maximum
diameters of hind limbs at the site of tumor injection were measured for
each mouse in the five groups at days 9 and 13 to gauge the rate of tumor
growth. The diameters of each hind limb of each mouse in each group were
averaged (n = 6, diamond) and the standard deviation of each group of data
(vertical bars) were calculated. The lines between days 9 and 13 connect
each group and imply the growth rate. (b) The numbers of mice surviving
B16 tumor growth are reported. The colors of the lines correspond to the
colors of the diamonds in (a). The black line was intentionally shifted down
and to the left to illustrate the overlap with the red line.
Additional file 5: Supplementary Figure S2: Activity of the c-Myc
internal ribosome entry site. Adobe PDF file demonstrating unusual
activity of the c-myc IRES. Varying efficiency of c-myc IRES-driven
translation. Plasmid pEF3-ChFPcmycEGFP was transfected using PEI into
293T cells, and the transiently transfected population subjected to
fluorescence-activated cell sorting. (Left) Intact cells were surrounded by
the region labeled R1 on a forward scatter (inset, horizontal):side scatter
(inset, vertical) contour plot. (Right) Disrupted cells were surrounded by
the region labeled R1 on a forward scatter (inset, horizontal):side scatter
(inset, vertical) contour plot. In both large figures, the R1-positively gated
cells were then analyzed for the EGFP and ChFP fluorescence by a FL1
(main, horizontal) versus FL3 (main, vertical) contour plot. Nonfluorescent
cells are surrounded by the R2-labeled polygon.
Additional file 6: Supplementary Figure S3: Analysis of pmaxGFP
versus pmaxCDK-TurboGFP. Adobe PDF file presenting a comparison
of expression of two plasmids. Expression of copepod GFPs from pmax-
based plasmids. Either PEI or Metafectene Easy (meta) were used to
transfect 293T cells, B16 cells, or MSCs with pmaxCDK-TurboGFP (Tur, left-
hand bars) or with pmaxGFP (ppl, right-hand bars). The upper bar graph
displays the transfection efficiency, while the bottom bar graph displays
the average FL1 fluorescence. It should be noted that, because the
fluorescence of ppluGFP encoded within pmaxGFP is more yellowish
than that of TurboGFP encoded within pmaxCDK, a larger fraction of
ppluGFP fluorescence will pass through the FL1 barrier filter (515 to 545
nm) than that of TurboGFP fluorescence; this partially accounts for
stronger FL1 fluorescence by pmaxGFP than by TurboGFP.
Additional file 7: Supplementary Figure S4: Apparent enhancement
of transfections with monoclonal antibodies. Adobe PDF file showing
increased transfection and expression using monoclonal antibodies. Effect
of neutralizing antibodies specific to Mu-IFNa on the transfection and
expression of pCMVi.5puro-MuIFNaAEMCVChFP. B16 cells were transfected
using Metafectene Easy with plasmid pCMVi.5puro-MuIFNaAEMCVChFP,
and were either left untreated or were treated with neutralizing monoclonal
antibodies raised against Mu-IFNa. (Left) The transfection efficiency (top)
and average ChFP levels (bottom) were determined by fluorescence-
activated cell sorting in the absence (black bars) and presence (gray bars) of
the monoclonal antibodies. (Right) Contour plots of FL1 (horizontal) versus
FL3 fluorescence are displayed of these cells. Untreated cells lie to the left,
while antibody-treated cells lie to the right.
Additional file 8: Supplementary Figure S5: Interferon dose-
dependant growth of mouse tumors. Adobe PDF file demonstrating the
second mouse experiment. Varying growth of B16 tumors in mice as a
function of dosage release of MSCs. (Top) The growth rates of 100,000
injected B16 melanoma cells were monitored in three mice per group co-
injected with monoclonal MSCs expressing Mu-IFNaA from the bicistronic
message MuIFNaAEMCVChFP at the following doses (from left to right): 200,
2,000 to 5,000, 18,000 to 25,000, 62,500, or with a monoclonal MSCs
expressing Mu-IFNaA from a monocistronic message at a dosage of 175,000
units/(10
6 cells/day). No growth is assumed if the tumor mass is below the
limit of palpation (about 125 mm
3). (Bottom) Assuming exponential growth
of tumors within mice, best-fit lines of the exponential growth rate and initial
tumor size were calculated on a semi-log plot (left). From these, values for
initial tumor size and doubling rate can be obtained (right).
Additional file 9: Supplementary Figure S6: Images of stably
transfected stem cells. Adobe PDF file showing stable transfection of
pPGK1.5hygro-based plasmids in MSCs. Transfections of pPGK1.5hygro-
MuIFNaAEMCVChFP (top row), pPGK1.5hygro-EGFPEMCVChFP (middle
row), and pPGK1.5hygro-TurboGFP (bottom panel) were done with
Metafectene Easy in MSCs; and after treatment with hygromycin (100 μg/
ml) for 2 weeks, cells were allowed to amplify to demonstrate their
ability to grow as stem cells. (Top panel) The left image is that of red
fluorescence; the middle image is that obtained with bright-field
illumination. The right-hand image is a merge of the left-hand two
images. The bright-field image was intentionally darkened to facilitate
visualizing the overlap of the two images. (Middle panel) The left image
is of red fluorescence; the right image is of green fluorescence. (Bottom
panel) Green fluorescence of the image is shown.
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ChFP: monomeric cherry fluorescent protein; CMV: cytomegalovirus; DMEM:
Dulbecco’s modified Eagle’s medium; EF1A: elongation factor-1α; ELISA:
enzyme-linked immunosorbent assay; EMCV: encephalomyocarditis virus;
FCS: fetal calf serum; GFP: monomeric green fluorescent protein; GOI: gene
of interest; IFN: interferon; IL: interleukin; IRES: internal ribosome entry site;
MSC: mesenchymal stem cell; ORF: open reading frame; PAGE:
polyacrylamide gel electrophoresis; PBS: phosphate-buffered saline; PCR:
polymerase chain reaction; PEI: polyethyleneimine; Pfu: Pyrococcus furiosus;
PGK: phosphoglycerate kinase; SV40: simian virus-40; Taq: Thermus aquaticus;
UTR: untranslated region.
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